Evaluation of the efficacy of Trastuzumab in patients with HER2 positive small (pT1mi/a) breast cancers. A multicenter retrospective study on 100 patients

Evaluation of the efficacy of Trastuzumab in patients with HER2 positive small (pT1mi/a) breast cancers. A multicenter retrospective study on 100 patients

Bibliographic Details
Main Authors:	A. Villasco, S. Actis, F. Borella, M. D’Alonzo, R. Ponzone, C. De Sanctis, C. Benedetto, N. Biglia
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977621000904

Similar Items

Surgery after Neoadjuvant Chemotherapy: A Clip-Based Technique to Improve Surgical Outcomes, a Single-Center Experience
by: Accomasso, F., et al.
Published: (2022)

Breast and axillary downstaging after neoadjuvant chemotherapy in breast cancer: surgical technique
by: M. D’Alonzo, et al.
Published: (2021-04-01)

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
by: Sietske B.M. Gaykema, et al.
Published: (2014-07-01)

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
by: Daisuke Kotani, et al.
Published: (2021-01-01)

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.
by: Stefania Gori, et al.
Published: (2016-01-01)

Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer
by: MENG Wenjing, et al.
Published: (2018-02-01)

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
by: Yi Li, et al.
Published: (2020-03-01)

Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series
by: Vincenzo Di Lauro, et al.
Published: (2012-01-01)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
by: Sawaki M
Published: (2014-04-01)

Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study
by: Hiroyasu Yamashiro, et al.
Published: (2018-07-01)

HER2-positive breast cancer with brain metastasis: long-lasting response after lapatinib treatment
by: Alessia D'Alonzo, et al.
Published: (2018-06-01)

Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients
by: Shuai Li, et al.
Published: (2021-07-01)

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
by: Qin T, et al.
Published: (2013-04-01)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
by: Alena Rudkouskaya, et al.
Published: (2020-12-01)

Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01)

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
by: Orlando Laura, et al.
Published: (2006-09-01)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
by: Jamunarani Veeraraghavan, et al.
Published: (2021-05-01)

Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells.
by: Senem Noyan, et al.
Published: (2019-01-01)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
by: Yue Hao, et al.
Published: (2019-01-01)

Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer
by: Yi-Tsung Yang, et al.
Published: (2014-12-01)

Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice
by: Nathalie I. Bouwer, et al.
Published: (2020-08-01)

Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
by: Sagar Sardesai, et al.
Published: (2020-11-01)

Adverse reactions for the use of the monoclonal trastuzumab antibody in the treatment of patients with HER2 positive breast cancer
by: Iago Dilion Lima Cavalcanti, et al.

miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines
by: Lihi Ninio-Many, et al.
Published: (2020-02-01)

Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison
by: Sapino Anna, et al.
Published: (2010-02-01)

Concerns and Expectations of Risk-Reducing Surgery in Women with Hereditary Breast and Ovarian Cancer Syndrome
by: Paola Modaffari, et al.
Published: (2019-03-01)

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)

An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases
by: A. S. Kolbin, et al.
Published: (2019-04-01)

NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
by: Nathalie I. Bouwer, et al.
Published: (2019-05-01)

Assessment of Carvedilol Therapy in Prevention of Heart Failure in HER2 Positive Breast Cancer Patients Receiving Trastuzumab
by: Alborz Sherafati, et al.
Published: (2019-05-01)

Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China
by: Zhou P, et al.
Published: (2016-04-01)

Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore
by: de Lima Lopes Gilberto
Published: (2011-05-01)

Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab
by: Elisabeth Sophie Bergen, et al.
Published: (2021-04-01)

MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6
by: Xiangdong Lu, et al.
Published: (2017-12-01)

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
by: Tiziana Triulzi, et al.
Published: (2019-01-01)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
by: Yue Hao, et al.
Published: (2019-01-01)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
by: Celia Nieto, et al.
Published: (2019-06-01)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
by: Babak Nami, et al.
Published: (2019-03-01)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
by: Gabriel L. Fiszman, et al.
Published: (2011-01-01)

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
by: Justin M Scheer, et al.
Published: (2012-01-01)